Merck’s Niacin Combination Drug To Be Evaluated In Heart Protection Study 2
This article was originally published in The Pink Sheet Daily
Executive Summary
$79.2 mil. THRIVE study will evaluate niacin in combination with an investigational prostaglandin D2 blocker in 20,000 patients.
You may also be interested in...
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Niaspan/Statin Combinations Improve Lipid Control, Study Shows
Addition of niacin to statin therapy demonstrates greater reductions in triglycerides and lipoprotein and increases in HDL-C.